1) rh-endostatin(YH-16)
重组人血管内皮抑制素YH-16
1.
Objective To investigate the response rate(RR), time to tumor progression(TTP), quality of life(QOL) and adverse reaction in the treatment of pretreated advanced non-small cell lung cancer (NSCLC) using escalated doses of rh-endostatin(YH-16), and to determine the optimal dose for clinical application.
目的评价重组人血管内皮抑制素YH-16治疗复治的晚期非小细胞肺癌的有效率、肿瘤进展时间(TTP)、对生活质量的影响及不良反应,并为临床确定合适的用药剂量。
2) recombinant human Endostatin
重组人血管内皮抑制素
1.
Clinical application of recombinant human endostatin
重组人血管内皮抑制素临床应用进展
2.
The fermentation process of recombinant human Endostatin expression in Escherichia coli BL21 (DE3) was studied.
优化了重组人血管内皮抑制素的E。
3.
In order to instruct reasonable application of the recombinant Human Endostatin ,the development in clinical research of Endostar for malignant tumor were reviewed in this paper,including clinical results,drug adverse reactions and qulity of life.
介绍重组人血管内皮抑制素(恩度)治疗恶性肿瘤的临床研究情况,包括临床疗效、不良反应和生活质量方面的研究进展,为临床合理应用和评价新药提供参考。
3) Homemade human rh-endostatin
重组人血管内皮抑制素
1.
Observation of early curative effect of homemade human rh-endostatin injection in combination with chemotherapy for advanced non-small cell lung cancer;
重组人血管内皮抑制素联合化疗治疗晚期非小细胞肺癌近期疗效观察
4) recombinant human endostatin
重组人血管内皮抑素
1.
Inhibitory effects of recombinant human endostatin on the metastatic potential and invasiveness of hepatocellular carcinoma HCCLM6 cells in vitro;
重组人血管内皮抑素体外对肝癌HCCLM6细胞转移侵袭的影响
2.
Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients;
心肌生化标志物联合检测评价重组人血管内皮抑素心脏毒性
3.
Intravenous drip transfusion of recombinant human endostatin combined with arterial infusion chemotherapy for the treatment of advanced carcinomas: a clinical observation
静脉滴注重组人血管内皮抑素联合动脉灌注化疗治疗晚期恶性肿瘤的临床观察
5) human recombinant endostatin
人重组血管内皮抑素
1.
Objective To study the effect of proliferation inhibition and induction of apoptosis of the A549 cell line of lung cancer and human umbilical vein endothelial cell ECV304 by gold nanoshell particles of human recombinant endostatin(Gold Silica Nanoshell-rhEndostatin,G-rhES) under near-infrared radiation of 820nm.
目的研究在820nm波长近红外线(near-infrared,NIR)照射下人重组血管内皮抑素/金纳米壳层(Gold Silica Nanoshell-rhEndostatin,G-rhES)对血管内皮细胞株ECV304及肺癌细胞株A549增殖抑制和诱导凋亡作用。
6) Rh-endostatin
重组人血管内皮抑素
1.
Objective:To observe the efficacy and safety of rh-endostatin injection (YH-16,Endostar),a new anti-tumor agent,combined with vinorelbine and cisplatin in first-line treatment of advanced non-small-cell lung cancer patients.
目的:观察抗肿瘤新药重组人血管内皮抑素(恩度)联合NP方案化疗在晚期NSCLC一线化疗中的近期疗效和安全性。
2.
Objective:To observe the efficacy and safety of rh-endostatin injection (YH-16,Endostar),a new molecular targeted anti-tumor agent,combined with the chemotherapy on multiple kind of advanced malignancies.
目的:观察恩度(重组人血管内皮抑素注射液,YH-16)联合化疗治疗多种晚期恶性肿瘤的有效性和安全性。
3.
Rh-endostatin in Combination with Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
目的观察抗肿瘤新药重组人血管内皮抑素注射液联合化疗治疗晚期NSCLC的有效性和安全性。
补充资料：silicic acid xSiO2·yH2O
分子式：
CAS号：
性质：无定形二氧化硅的水合物。白色胶冻状或絮状固体。目前被确认的有正硅酸(原硅酸)H4SiO4(x=1,y=2)、偏硅酸H2SiO3(x=1,y=1)、二硅酸H2Si2O5(x=2,y=1)、焦硅酸H6Si2O7(x=2,y=3)。硅酸组成复杂，随条件而异。水中溶解度较小。呈弱酸性。由可溶性硅酸盐稀溶液和酸作用制得正硅酸的不稳定水溶液，失水成偏硅酸即通称的硅酸。放置能缩合成多分子聚合物称硅酸溶胶(mSiO2·nH2O)，简称硅溶胶，加热脱水可得硅胶(多孔SiO2含水4%)。由细孔球形硅胶用盐酸浸泡4～6h后用纯水洗涤，烘干72h，用纯水洗涤，再在70～80℃二次烘干制得。也可由硅酸钠与硫酸反应生成硅溶胶，经凝聚，一次洗涤，干燥，浓盐酸浸泡，二次洗涤，干燥而制得。用作气体的吸附剂，油脂和蜡等的脱色剂，催化剂载体，以及分析化学试剂等。
CAS号：
性质：无定形二氧化硅的水合物。白色胶冻状或絮状固体。目前被确认的有正硅酸(原硅酸)H4SiO4(x=1,y=2)、偏硅酸H2SiO3(x=1,y=1)、二硅酸H2Si2O5(x=2,y=1)、焦硅酸H6Si2O7(x=2,y=3)。硅酸组成复杂，随条件而异。水中溶解度较小。呈弱酸性。由可溶性硅酸盐稀溶液和酸作用制得正硅酸的不稳定水溶液，失水成偏硅酸即通称的硅酸。放置能缩合成多分子聚合物称硅酸溶胶(mSiO2·nH2O)，简称硅溶胶，加热脱水可得硅胶(多孔SiO2含水4%)。由细孔球形硅胶用盐酸浸泡4～6h后用纯水洗涤，烘干72h，用纯水洗涤，再在70～80℃二次烘干制得。也可由硅酸钠与硫酸反应生成硅溶胶，经凝聚，一次洗涤，干燥，浓盐酸浸泡，二次洗涤，干燥而制得。用作气体的吸附剂，油脂和蜡等的脱色剂，催化剂载体，以及分析化学试剂等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条